Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
RESEARCH TOOLSreports
Total Valuation
Takeda Pharmaceutical Company has a market cap or net worth of $47.96B. The enterprise value is $70.87B.
Market Cap$47.96B
Enterprise Value$70.87B
Share Statistics
Takeda Pharmaceutical Company has 3,181,899,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,181,899,200
Owned by Insiders―
Owned by Institutions0.03%
Financial Efficiency
Takeda Pharmaceutical Company’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 4.44%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)4.44%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee86.52M
Profits Per Employee2.92M
Employee Count49,281
Asset Turnover0.28
Inventory Turnover1.18
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Company is 45.02. Takeda Pharmaceutical Company’s PEG ratio is -0.82.
PE Ratio45.02
PS Ratio0.00
PB Ratio0.89
Price to Fair Value0.89
Price to FCF27.53
Price to Operating Cash Flow9.05
PEG Ratio-0.82
Income Statement
In the last 12 months, Takeda Pharmaceutical Company had revenue of 4.26T and earned 144.07B in profits. Earnings per share was 92.09.
Revenue4.26T
Gross Profit2.83T
Operating Income214.07B
Pretax Income52.79B
Net Income144.07B
EBITDA874.60B
Earnings Per Share (EPS)92.09
Cash Flow
In the last 12 months, operating cash flow was 837.30B and capital expenditures -328.72B, giving a free cash flow of 508.58B billion.
Operating Cash Flow837.30B
Free Cash Flow508.58B
Free Cash Flow per Share159.83
Dividends & Yields
Takeda Pharmaceutical Company pays an annual dividend of $0.319, resulting in a dividend yield of 3.84%
Dividend Per Share$0.319
Dividend Yield3.84%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.10
52-Week Price Change19.92%
50-Day Moving Average14.60
200-Day Moving Average13.76
Relative Strength Index (RSI)62.18
Average Volume (3m)2.20M
Important Dates
Takeda Pharmaceutical Company upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateJan 30, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend DateMar 31, 2025
Financial Position
Takeda Pharmaceutical Company as a current ratio of 1.11, with Debt / Equity ratio of 72.99%
Current Ratio1.11
Quick Ratio0.58
Debt to Market Cap0.75
Net Debt to EBITDA5.01
Interest Coverage Ratio1.39
Taxes
In the past 12 months, Takeda Pharmaceutical Company has paid -91.41B in taxes.
Income Tax-91.41B
Effective Tax Rate-1.73
Enterprise Valuation
Takeda Pharmaceutical Company EV to EBITDA ratio is 8.72, with an EV/FCF ratio of 32.38.
EV to Sales1.79
EV to EBITDA8.72
EV to Free Cash Flow32.38
EV to Operating Cash Flow10.65
Balance Sheet
Takeda Pharmaceutical Company has $906.22B in cash and marketable securities with ¥18.80B in debt, giving a net cash position of $4.14T billion.
Cash & Marketable Securities$906.22B
Total Debt¥18.80B
Net Cash$4.14T
Net Cash Per Share$1.30K
Tangible Book Value Per Share-$1.54K
Margins
Gross margin is 55.23%, with operating margin of 5.02%, and net profit margin of 3.38%.
Gross Margin55.23%
Operating Margin5.02%
Pretax Margin1.24%
Net Profit Margin3.38%
EBITDA Margin20.51%
EBIT Margin4.04%
Analyst Forecast
The average price target for Takeda Pharmaceutical Company is $36.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$36.71
Price Target Upside140.09% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast1.92%
EPS Growth Forecast6.40%